凯信远达(CASI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CASI 凯信远达

交易中 02-13 11:36:15 EST

0.8759

+0.1355

+18.30%

最高0.8760	最低0.7811	成交量3,764
今开0.7811	昨收0.7404	日振幅12.82%
总市值1,800万	流通市值817.63万	总股本2,055万
成交额3,203	换手率0.04%	流通股本933.47万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CASI","market":"US","secType":"STK","nameCN":"凯信远达","latestPrice":0.8759,"timestamp":1771000490856,"preClose":0.7404,"halted":0,"volume":3764,"delay":0,"changeRate":0.1830091842247435,"floatShares":9334700,"shares":20548273,"eps":-2.984515,"marketStatus":"交易中","change":0.1355,"latestTime":"02-13 11:36:15 EST","open":0.7811,"high":0.876,"low":0.7811,"amount":3202.813948,"amplitude":0.128174,"askPrice":0.9689,"askSize":5,"bidPrice":0.8,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-2.984515,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771016400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":834552000000,"exchange":"NASDAQ","adjPreClose":0.7404,"postHourTrading":{"tag":"盘后","latestPrice":0.7484,"preClose":0.7484,"latestTime":"16:04 EST","volume":2,"amount":1.4808,"timestamp":1770930273058,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.462731,"impliedVol":0.1099,"impliedVolPercentile":0.243},"requestUrl":"/m/hq/s/CASI/wiki","defaultTab":"wiki","newsList":[{"id":"2602658864","title":"凯信远达盘中异动 股价大涨8.93%报1.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602658864","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602658864?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:33","pubTimestamp":1767969217,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日22时33分，凯信远达股票出现异动，股价快速上涨8.93%。截至发稿，该股报1.16美元/股，成交量2.0057万股，换手率0.10%，振幅5.63%。凯信远达股票所在的生物技术行业中，整体涨幅为0.71%。这些产品包括为患有白血病和淋巴瘤的患者注射。迈维宁注射液用作多发性骨髓瘤患者自体干细胞移植前的预处理治疗。大部分收入来自迈维宁的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109223337a707c784&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109223337a707c784&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"1188102807","title":"何伟武计划通过债股结合方式为提案交易融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1188102807","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188102807?lang=zh_cn&edition=full","pubTime":"2026-01-09 19:14","pubTimestamp":1767957286,"startTime":"0","endTime":"0","summary":"凯信远达（CASI Pharmaceuticals）董事长何伟武近日披露，公司拟通过债务与股权相结合的融资方案，为提案中规划的多项交易提供资金支持。\n该混合融资策略旨在优化资本结构，平衡财务杠杆与股东权益。市场分析人士指出，这种融资方式既能缓解短期现金流压力，又可为长期战略布局保留弹性空间。\n据悉，相关交易细节仍在进一步论证中，具体债务比例与股权稀释程度将根据市场条件和投资者反馈动态调整。此举反映出企业在复杂经济环境下对资金配置的审慎考量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CASI","BK4139"],"gpt_icon":0},{"id":"1188459250","title":"何伟武于1月9日向凯信远达董事会提交更新版初步非约束性收购建议函——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1188459250","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188459250?lang=zh_cn&edition=full","pubTime":"2026-01-09 19:13","pubTimestamp":1767957197,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新公开文件显示，何伟武已于1月9日正式向凯信远达（CASI Pharmaceuticals）董事会递交了更新版的初步非约束性收购建议函。该提案目前仍处于初步阶段，且不具备法律约束力，标志着收购方对目标公司的战略意图进入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CASI","BK4139"],"gpt_icon":0},{"id":"1148610518","title":"凯信远达 - 投资用于资助中国阶段1肾移植抗体介导排斥反应研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1148610518","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148610518?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:12","pubTimestamp":1765462338,"startTime":"0","endTime":"0","summary":"凯信远达 - 投资用于资助中国阶段1肾移植抗体介导排斥反应研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"2582308936","title":"凯信远达盘中异动 股价大涨5.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582308936","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582308936?lang=zh_cn&edition=full","pubTime":"2025-11-12 04:59","pubTimestamp":1762894787,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日04时59分，凯信远达股票出现波动，股价急速上涨5.60%。截至发稿，该股报1.42美元/股，成交量2.4033万股，换手率0.16%，振幅6.72%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。凯信远达股票所在的生物技术行业中，整体涨幅为1.65%。这些产品包括为患有白血病和淋巴瘤的患者注射。大部分收入来自迈维宁的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112045947a49a8f0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112045947a49a8f0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CASI","BK4139"],"gpt_icon":0},{"id":"2582872352","title":"凯信远达盘中异动 急速下跌5.07%报1.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582872352","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582872352?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:15","pubTimestamp":1762787742,"startTime":"0","endTime":"0","summary":"北京时间2025年11月10日23时15分，凯信远达股票出现波动，股价大幅下挫5.07%。截至发稿，该股报1.31美元/股，成交量1.5851万股，换手率0.10%，振幅4.35%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。凯信远达股票所在的生物技术行业中，整体涨幅为0.73%。这些产品包括为患有白血病和淋巴瘤的患者注射。大部分收入来自迈维宁的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111023154397608193&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111023154397608193&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CASI","BK4139"],"gpt_icon":0},{"id":"2580491619","title":"凯信远达盘中异动 早盘股价大涨5.88%报1.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580491619","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580491619?lang=zh_cn&edition=full","pubTime":"2025-10-31 21:32","pubTimestamp":1761917553,"startTime":"0","endTime":"0","summary":"北京时间2025年10月31日21时32分，凯信远达股票出现异动，股价快速上涨5.88%。截至发稿，该股报1.44美元/股，成交量4269股，换手率0.03%，振幅0.00%。凯信远达股票所在的生物技术行业中，整体跌幅为0.28%。这些产品包括为患有白血病和淋巴瘤的患者注射。迈维宁注射液用作多发性骨髓瘤患者自体干细胞移植前的预处理治疗。大部分收入来自迈维宁的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031213233a6d90708&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031213233a6d90708&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"2577149445","title":"凯信远达盘中异动 股价大涨8.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577149445","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577149445?lang=zh_cn&edition=full","pubTime":"2025-10-24 21:36","pubTimestamp":1761312962,"startTime":"0","endTime":"0","summary":"北京时间2025年10月24日21时36分，凯信远达股票出现异动，股价急速上涨8.70%。截至发稿，该股报1.75美元/股，成交量434股，换手率0.00%，振幅0.00%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。凯信远达股票所在的生物技术行业中，整体涨幅为0.32%。这些产品包括为患有白血病和淋巴瘤的患者注射。大部分收入来自迈维宁的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024213602a472dc94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024213602a472dc94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CASI","BK4139"],"gpt_icon":0},{"id":"2574857101","title":"凯信远达盘中异动 股价大涨6.99%报1.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574857101","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574857101?lang=zh_cn&edition=full","pubTime":"2025-10-08 21:50","pubTimestamp":1759931457,"startTime":"0","endTime":"0","summary":"北京时间2025年10月08日21时50分，凯信远达股票出现异动，股价快速拉升6.99%。截至发稿，该股报1.99美元/股，成交量2.9766万股，换手率0.19%，振幅2.15%。凯信远达股票所在的生物技术行业中，整体涨幅为0.15%。这些产品包括为患有白血病和淋巴瘤的患者注射。迈维宁注射液用作多发性骨髓瘤患者自体干细胞移植前的预处理治疗。大部分收入来自迈维宁的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100821505894bf2c99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100821505894bf2c99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"2573798168","title":"凯信远达盘中异动 早盘大幅拉升8.11%报2.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2573798168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573798168?lang=zh_cn&edition=full","pubTime":"2025-10-06 21:31","pubTimestamp":1759757470,"startTime":"0","endTime":"0","summary":"北京时间2025年10月06日21时31分，凯信远达股票出现异动，股价大幅拉升8.11%。截至发稿，该股报2.00美元/股，成交量1895股，换手率0.01%，振幅0.00%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。凯信远达股票所在的生物技术行业中，整体涨幅为0.00%。这些产品包括为患有白血病和淋巴瘤的患者注射。大部分收入来自迈维宁的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251006213110a6aed94c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251006213110a6aed94c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"2572062652","title":"凯信远达盘中异动 股价大涨5.71%报1.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572062652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572062652?lang=zh_cn&edition=full","pubTime":"2025-10-03 21:31","pubTimestamp":1759498271,"startTime":"0","endTime":"0","summary":"北京时间2025年10月03日21时31分，凯信远达股票出现异动，股价大幅拉升5.71%。截至发稿，该股报1.85美元/股，成交量881股，换手率0.01%，振幅0.00%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。凯信远达股票所在的生物技术行业中，整体涨幅为0.33%。这些产品包括为患有白血病和淋巴瘤的患者注射。大部分收入来自迈维宁的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003213111a6ac2d00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003213111a6ac2d00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"2566607380","title":"凯信远达上涨2.14%，报2.39美元/股，总市值3706.02万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566607380","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566607380?lang=zh_cn&edition=full","pubTime":"2025-09-10 22:04","pubTimestamp":1757513081,"startTime":"0","endTime":"0","summary":"据交易所数据显示，9月10日，凯信远达盘中上涨2.14%，截至22:04，报2.39美元/股，成交6.26万美元，总市值3706.02万美元。财务数据显示，截至2025年03月31日，凯信远达收入总额624.0万美元，同比增长83.04%；归母净利润-1075.0万美元，同比减少12.83%。大事提醒：8月29日，凯信远达披露2025财年中报。资料显示，凯信远达医药公司是一家美国纳斯达克上市的生物医药公司,致力于在血液肿瘤领域为中国患者提供先进的疾病治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/09/10220453060084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CASI","BK4139"],"gpt_icon":0},{"id":"1133012160","title":"CASI Pharmaceuticals Inc宣布Folotyn®在华进口药品注册证过期","url":"https://stock-news.laohu8.com/highlight/detail?id=1133012160","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133012160?lang=zh_cn&edition=full","pubTime":"2025-08-28 04:51","pubTimestamp":1756327877,"startTime":"0","endTime":"0","summary":"CASI Pharmaceuticals Inc（凯信远达）宣布其产品Folotyn®在中国的进口药品注册证已过期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"2518208822","title":"凯信远达盘中异动 股价大涨5.45%报2.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208822","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518208822?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:26","pubTimestamp":1741624003,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日00时26分，凯信远达股票出现异动，股价快速拉升5.45%。截至发稿，该股报2.32美元/股，成交量3699股，换手率0.02%，振幅4.55%。凯信远达股票所在的生物技术行业中，整体涨幅为0.43%。凯信远达公司简介：CASI Pharmaceuticals Inc是一家生物制药公司，致力于将创新疗法和药物产品商业化。该产品包括针对患有白血病和淋巴瘤的患者的注射剂。EVOMELA注射液用于多发性骨髓瘤患者自体干细胞移植前作为条件治疗。大部分收入来自EVOMELA的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031100264398a2c0fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031100264398a2c0fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CASI","BK4139"],"gpt_icon":0},{"id":"2517944039","title":"凯信远达盘中异动 股价大涨8.77%报2.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944039","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517944039?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:30","pubTimestamp":1741192214,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时30分，凯信远达股票出现波动，股价快速上涨8.77%。截至发稿，该股报2.48美元/股，成交量1727股，换手率0.01%，振幅0.00%。凯信远达股票所在的生物技术行业中，整体涨幅为1.12%。凯信远达公司简介：CASI Pharmaceuticals Inc是一家生物制药公司，致力于将创新疗法和药物产品商业化。该产品包括针对患有白血病和淋巴瘤的患者的注射剂。EVOMELA注射液用于多发性骨髓瘤患者自体干细胞移植前作为条件治疗。大部分收入来自EVOMELA的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306003014abe9d509&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306003014abe9d509&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"2516729652","title":"凯信远达盘中异动 下午盘快速上涨9.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516729652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516729652?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:46","pubTimestamp":1741027600,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时46分，凯信远达股票出现波动，股价大幅拉升9.33%。截至发稿，该股报2.46美元/股，成交量491股，换手率0.00%，振幅0.00%。凯信远达股票所在的生物技术行业中，整体涨幅为0.59%。凯信远达公司简介：CASI Pharmaceuticals Inc是一家生物制药公司，致力于将创新疗法和药物产品商业化。该产品包括针对患有白血病和淋巴瘤的患者的注射剂。EVOMELA注射液用于多发性骨髓瘤患者自体干细胞移植前作为条件治疗。大部分收入来自EVOMELA的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304024640abe67bdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304024640abe67bdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CASI","BK4139"],"gpt_icon":0},{"id":"2514103017","title":"凯信远达盘中异动 大幅跳水6.48%报2.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514103017","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514103017?lang=zh_cn&edition=full","pubTime":"2025-02-26 01:43","pubTimestamp":1740505381,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日01时43分，凯信远达股票出现异动，股价快速跳水6.48%。截至发稿，该股报2.26美元/股，成交量7485股，换手率0.05%，振幅3.72%。凯信远达股票所在的生物技术行业中，整体涨幅为0.59%。凯信远达公司简介：CASI Pharmaceuticals Inc是一家生物制药公司，致力于将创新疗法和药物产品商业化。该产品包括针对患有白血病和淋巴瘤的患者的注射剂。EVOMELA注射液用于多发性骨髓瘤患者自体干细胞移植前作为条件治疗。大部分收入来自EVOMELA的产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226014302abdcaa8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226014302abdcaa8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"2512198750","title":"凯信远达上涨2.2%，报2.555美元/股，总市值3958.35万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512198750","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512198750?lang=zh_cn&edition=full","pubTime":"2025-02-19 01:42","pubTimestamp":1739900566,"startTime":"0","endTime":"0","summary":"2月19日，凯信远达盘中上涨2.2%，截至01:42，报2.555美元/股，成交5294.0美元，总市值3958.35万美元。财务数据显示，截至2024年09月30日，凯信远达收入总额1518.1万美元，同比减少43.78%；归母净利润-2488.8万美元，同比减少19.18%。大事提醒：3月27日，凯信远达将披露2024财年年报。资料显示，凯信远达医药公司是一家美国纳斯达克上市的生物医药公司,致力于在血液肿瘤领域为中国患者提供先进的疾病治疗方案。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/19014248243218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"2511572054","title":"凯信远达上涨2.36%，报2.6美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2511572054","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511572054?lang=zh_cn&edition=full","pubTime":"2025-02-14 04:46","pubTimestamp":1739479578,"startTime":"0","endTime":"0","summary":"2月14日，凯信远达(CASI)盘中上涨2.36%，截至04:46，报2.6美元/股，成交1.68万美元。财务数据显示，截至2024年09月30日，凯信远达收入总额1518.1万美元，同比减少43.78%；归母净利润-2488.8万美元，同比减少19.18%。大事提醒：3月27日，凯信远达将披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/14044648151014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"2510861944","title":"凯信远达上涨5.69%，报2.6美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2510861944","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510861944?lang=zh_cn&edition=full","pubTime":"2025-02-10 23:35","pubTimestamp":1739201743,"startTime":"0","endTime":"0","summary":"2月10日，凯信远达(CASI)盘中上涨5.69%，截至23:35，报2.6美元/股，成交2147.0美元。财务数据显示，截至2024年09月30日，凯信远达收入总额1518.1万美元，同比减少43.78%；归母净利润-2488.8万美元，同比减少19.18%。大事提醒：3月27日，凯信远达将披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/10233548064213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CASI","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.casipharmaceuticals.com","stockEarnings":[{"period":"1week","weight":-0.2122},{"period":"1month","weight":-0.2804},{"period":"3month","weight":-0.406},{"period":"6month","weight":-0.6855},{"period":"1year","weight":-0.7054},{"period":"ytd","weight":-0.1195}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"凯信远达医药公司于1991年注册成立，是一家在开曼群岛注册成立的豁免公司。该公司是一家生物制药公司，专注于在中国、美国和世界各地开发和商业化创新疗法和医药产品。公司打造了一家完全一体化、世界一流的生物制药公司，致力于创新和其他治疗产品的成功开发和商业化。公司业务发展战略目前的重点是通过许可获得额外的靶向药物和免疫肿瘤疗法，这将扩大血液学/肿瘤学特许经营权。","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.166552},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.018621},{"month":3,"riseRate":0.310345,"avgChangeRate":-0.000942},{"month":4,"riseRate":0.37931,"avgChangeRate":0.030827},{"month":5,"riseRate":0.241379,"avgChangeRate":0.04909},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.032316},{"month":7,"riseRate":0.266667,"avgChangeRate":-0.055599},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.00385},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.001431},{"month":10,"riseRate":0.6,"avgChangeRate":0.088727},{"month":11,"riseRate":0.366667,"avgChangeRate":0.020646},{"month":12,"riseRate":0.233333,"avgChangeRate":-0.100731}],"exchange":"NASDAQ","name":"凯信远达","nameEN":"CASI Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯信远达(CASI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯信远达(CASI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯信远达,CASI,凯信远达股票,凯信远达股票老虎,凯信远达股票老虎国际,凯信远达行情,凯信远达股票行情,凯信远达股价,凯信远达股市,凯信远达股票价格,凯信远达股票交易,凯信远达股票购买,凯信远达股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯信远达(CASI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯信远达(CASI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}